10/31/14 JBSS 37.15 John B. Sanfilippo & Son $JBSS Hit a 52

New Post Public Reply Private Reply Replies (0) Message Board

Nov 2, 2014 at 1:42 AM

10/31/14 JBSS 37.15 John B. Sanfilippo & Son $JBSS Hit a 52 week high of 37.35 Closing the day 10/31/14 at 37.15 +0.80 +2.20% With a day low of 36.62 and a total volume of 49,500.

JBSS Recent Posts: http://investorshangout.com/John-B-Sanfilippo...BSS-54529/

JBSS John B. Sanfilippo & Son Recent Headline News

John B. Sanfilippo & Son, Inc. Board Declares Special Cash Dividend of $1.50 per share of Common Stock and $1.50 per share of Class A Common Stock
Business Wire - Tue Oct 28, 4:04PM CDT
John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the "Company"

today announced that its Board of Directors (the "Board"

declared a special cash dividend (the "Dividend"

of $1.50 per share on all issued and outstanding shares of Common Stock of the Company and $1.50 per share on all issued and outstanding shares of Class A Common Stock of the Company.
JBSS: 37.15 (+0.80)

John B. Sanfilippo & Son, Inc. Net Sales Increased by 16% on Higher Pricing and Strong Sales Volume
Business Wire - Thu Oct 23, 3:10PM CDT
--Net sales increased by 16.0%
JBSS: 37.15 (+0.80)

Shares of JBSS Up 43.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 20, 9:09AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 6 months, John B. Sanfilippo & Son has returned 43.68% as of today's recent price of $35.03.
JBSS: 37.15 (+0.80)

John B. Sanfilippo & Son, Inc. 1st Quarter Fiscal 2015 Operating Results Conference Call
GlobeNewswire - Fri Oct 17, 4:00PM CDT
John B. Sanfilippo & Son, Inc. (Nasdaq:JBSS), a major processor and distributor of snack and recipe nut products, will hold its quarterly conference call to discuss first quarter fiscal 2015 operating results on Friday, October 24, 2014 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). First quarter fiscal 2015 results are expected to be released after the market closes on Thursday, October 23, 2014.
JBSS: 37.15 (+0.80)

John B. Sanfilippo & Son Has Returned 34.3% Since SmarTrend Recommendation (JBSS)
Comtex SmarTrend(R) - Fri Oct 10, 5:11PM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 34.33% as of today's recent price of $32.75.
JBSS: 37.15 (+0.80)

John B. Sanfilippo & Son Up 32.9% Since SmarTrend Uptrend Call (JBSS)
Comtex SmarTrend(R) - Fri Oct 03, 4:45PM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 32.90% as of today's recent price of $32.40.
JBSS: 37.15 (+0.80)

Fisher Announces Statewide Campaign and $40,000 Donation to Feeding Texas
PR Newswire - Fri Oct 03, 9:00AM CDT
Fisher® Nuts announced a statewide campaign to bring Texas communities together to help feed hungry families this holiday season. In its third year partnering with Feeding Texas (formerly the Texas Food Bank Network) for the Fisher Shares & Cares campaign, Fisher is donating $40,000 that will be used to help feed 400,000 Texans throughout the season.
JBSS: 37.15 (+0.80)

33.6% Return Seen to Date on SmarTrend John B. Sanfilippo & Son Call (JBSS)
Comtex SmarTrend(R) - Fri Sep 26, 10:58AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 33.55% as of today's recent price of $32.56.
JBSS: 37.15 (+0.80)

Shares of JBSS Up 32.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 19, 9:36AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 32.32% as of today's recent price of $32.26.
JBSS: 37.15 (+0.80)

Uptrend Call Working As John B. Sanfilippo & Son Stock Rises 33.0% (JBSS)
Comtex SmarTrend(R) - Fri Sep 12, 9:10AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 4 months, John B. Sanfilippo & Son has returned 32.98% as of today's recent price of $32.42.
JBSS: 37.15 (+0.80)

Fisher Nuts and Chef Alex Guarnaschelli Announce Second Annual "My Fresh Twist" Recipe Contest
PR Newswire - Tue Sep 09, 10:45AM CDT
Fisher® Nuts has announced the second annual "My Fresh Twist" recipe contest today. Beginning now through October 21, 2014 consumers are invited to submit an original recipe using walnuts, almonds or pecans to www.myfreshtwist.com for a chance to win a grand prize that includes a trip for two to New York City to meet Chef Alex Guarnaschelli.
JBSS: 37.15 (+0.80)

John B. Sanfilippo & Son Has Returned 27.8% Since SmarTrend Recommendation (JBSS)
Comtex SmarTrend(R) - Thu Aug 28, 10:58AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 4 months, John B. Sanfilippo & Son has returned 27.75% as of today's recent price of $31.15.
JBSS: 37.15 (+0.80)

John B. Sanfilippo & Son Shares Up 21.3% Since SmarTrend's Buy Recommendation (JBSS)
Comtex SmarTrend(R) - Thu Aug 21, 9:40AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 4 months, John B. Sanfilippo & Son has returned 21.33% as of today's recent price of $29.58.
JBSS: 37.15 (+0.80)

John B. Sanfilippo & Son, Inc. Fourth Quarter EPS Increased by 15.7% to a Fourth Quarter Record $0.59 per Share Diluted
Business Wire - Tue Aug 19, 3:10PM CDT
--Net sales increased by 14.2%
JBSS: 37.15 (+0.80)

Shares of JBSS Up 10.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Aug 14, 9:24AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 4 months, John B. Sanfilippo & Son has returned 10.91% as of today's recent price of $27.04.
JBSS: 37.15 (+0.80)

John B. Sanfilippo & Son, Inc. 4th Quarter and Fiscal 2014 Year End Operating Results Conference Call
GlobeNewswire - Wed Aug 13, 4:33PM CDT
John B. Sanfilippo & Son, Inc. (Nasdaq:JBSS), a major processor and distributor of snack and recipe nut products, will hold its quarterly conference call to discuss fourth quarter and fiscal 2014 year end operating results on Wednesday, August 20, 2014 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). Fourth quarter and fiscal 2014 year end results are expected to be released after the market closes on Tuesday, August 19, 2014.
JBSS: 37.15 (+0.80)

12.2% Return Seen to Date on SmarTrend John B. Sanfilippo & Son Call (JBSS)
Comtex SmarTrend(R) - Wed Jul 09, 11:23AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 2 months, John B. Sanfilippo & Son has returned 12.22% as of today's recent price of $27.36.
JBSS: 37.15 (+0.80)

Relationships, Investing, and 1 "Real Value" Stock Pick
Adem Tahiri, The Motley Fool - Motley Fool - Mon Mar 10, 1:50PM CDT
What do relationships and investing have in common? They both tend to go sour when you over-think them. Image courtesy of Dr. Phil Don't worry, I'm not going to go "Dr. Phil" on you. But investing is really best when it's thought of as a...
DMND: 30.15 (+0.93), JBSS: 37.15 (+0.80), BEAM: 83.47 (+0.02)

Fisher Nuts Donates 200,000 Meals to Help Fight Hunger in Texas this Holiday Season
PR Newswire - Fri Dec 20, 7:00AM CST
For the second consecutive year, Fisher® Nuts donated 200,000 meals through a $20,000 donation to the San Antonio Food Bank and the Texas Food Bank Network (TFBN). More than 35 local employees from the Fisher plant in Selma, Texas joined TFBN volunteers for a check presentation ceremony and spent the morning volunteering their time and packing up holiday meals for families in need as part of the Fisher "Shares & Cares" Campaign.
JBSS: 37.15 (+0.80)

Sanfilippo (John B.) & Son Inc. (JBSS) Stock Research Links

JBSS Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Protecting Teeth: Insights from Endodontist Dr. Joubert

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...